Michael J. Overman, MD

Michael J. Overman, MD, discusses future research directions in gastrointestinal cancers.

Michael J. Overman, MD, discusses the rationale for utilizing a nonoperative management approach over traditional surgery in gastrointestinal cancers.

Michael J. Overman, MD, discusses the potential use of endoscopy and ctDNA to guide nonoperative management approaches in gastrointestinal cancers.

Michael J. Overman, MD, discusses potential applications for circulating tumor DNA in colorectal cancer.

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).

Michael J. Overman, MD, discusses factors to consider when choosing between regorafenib and TAS-102 in the third-line treatment of patients with colorectal cancer.

Michael J. Overman, MD, discusses second-line therapy options for patients with colorectal cancer.

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses investigational targeted therapies in metastatic colorectal cancer (mCRC).

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses tailoring approaches to molecular subsets of patients with metastatic colorectal cancer.

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses unmet needs with immunotherapy in metastatic colorectal cancer.

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the ReDOS study in patients with metastatic colorectal cancer.

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses progress made with immunotherapy agents in gastrointestinal (GI) cancer.

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses next steps with immunotherapy in the treatment of patients with metastatic colorectal cancer.

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in hepatocellular carcinoma (HCC).

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the impact of nivolumab (Opdivo) on the treatment of patients with metastatic colorectal cancer (mCRC).

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the remaining questions with immunotherapy in colorectal cancer.

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy and microsatellite instability (MSI) testing in colorectal caner (CRC).

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses nivolumab (Opdivo) in patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic CRC.

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the updated findings from CheckMate-142 in metastatic colorectal cancer during the 2018 Gastrointestinal Cancers Symposium.

Michael J. Overman, MD, medical oncologist, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated results from the CheckMate 142 trial, which investigated nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) in patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses how the results of the phase III FIRE-3 and 80405 studies will impact treatment of patients with metastatic colorectal cancer.

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) monotherapy, ipilimumab (Yervoy) monotherapy, and the combination of nivolumab and ipilimumab in patients with high microsatellite instability metastatic colorectal cancer.